Get the Stockscreener App
5.10
2.11%
-0.11
Evommune Inc stock is traded at $5.10, with a volume of 280.83K.
It is down -2.11% in the last 24 hours and down -39.93% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$5.21
Open:
$5.18
24h Volume:
280.83K
Relative Volume:
0.56
Market Cap:
$185.09M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-2.1363
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
-3.23%
1M Performance:
-39.93%
6M Performance:
-79.91%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$4.94
$5.70
52-Week Range:
$4.94
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
5.10 | 185.09M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-26 | Resumed | Morgan Stanley | Overweight |
| Oct-12-26 | Initiated | UBS | Neutral |
| Aug-26-26 | Initiated | Needham | Buy |
| Jun-30-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-29-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-01-26 | Initiated | Stifel | Buy |
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune stock initiated at Overweight by Morgan Stanley on dermatitis drug potential - Investing.com
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake - MarketBeat
Evommune, Inc. (EVMN) options chain - Yahoo Finance Australia
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September - Investing.com India
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September By Investing.com - Investing.com South Africa
At 85% of the closing price, Evommune (EVMN) CEO acquires 1,115 shares through an employee plan. - Stock Titan
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS Group - MarketBeat
Evommune, Inc. (EVMN) Receives a Hold from UBS - The Globe and Mail
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Moomoo
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Yahoo Finance
UBS Initiates Evommune(EVMN.US) With Hold Rating, Announces Target Price $8 - Moomoo
UBS initiates Evommune stock coverage with neutral rating on AD potential - Investing.com Nigeria
Long-acting EVO301 Shows Promise in Proof-of-concept AD Study - The Dermatology Digest
Evommune Inc (EVMN-N) Stock Price and News - The Globe and Mail
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - BioSpace
Evommune presents Phase 2a atopic dermatitis trial data - Investing.com
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Yahoo! Finance Canada
Evommune (NYSE:EVMN)Stock Analysis - Simply Wall Street
Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $33.33 According to Analysts - MarketBeat
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance Australia
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - Yahoo Finance
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Canada
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com India
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Canada
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
RBC cuts Evommune stock price target on drug trial setback - Investing.com
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evommune Inc Stock (EVMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRSCH ARTHUR S | Director |
Jul 07 '26 |
Buy |
13.30 |
10,000 |
133,000 |
10,000 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Sale |
22.63 |
20,000 |
452,600 |
67,794 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Option Exercise |
3.84 |
1,488 |
5,714 |
47,891 |
| JANICE DREW | Officer |
Jun 22 '26 |
Proposed Sale |
21.36 |
20,000 |
427,200 |
0 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Sale |
22.50 |
1,488 |
33,480 |
46,403 |
| Pena Luis C. | President & CEO |
Jun 22 '26 |
Sale |
22.71 |
7,438 |
168,917 |
630,458 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Option Exercise |
3.15 |
20,000 |
63,063 |
87,794 |
| Cohen David E | Director |
Jun 02 '26 |
Sale |
20.33 |
6,056 |
123,094 |
17,609 |
| DAVID COHEN | Director |
Jun 02 '26 |
Proposed Sale |
22.17 |
9,258 |
205,250 |
0 |
| LUIS PENA | Director |
Jun 01 '26 |
Proposed Sale |
23.23 |
24,225 |
562,747 |
0 |
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):